Lauren McCann Selected Research

Disease Progression

4/2013

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lauren McCann Research Topics

Disease

9	Renal Cell Carcinoma (Grawitz Tumor) 04/2016 - 01/2010
1	Cystic Fibrosis (Mucoviscidosis) 12/2016
1	Hypertension (High Blood Pressure) 01/2016
1	Neoplasm Metastasis (Metastasis) 01/2015
1	Kidney Neoplasms (Kidney Cancer) 11/2013
1	Hand-Foot Syndrome 08/2013
1	Clear-cell metastatic renal cell carcinoma 08/2013
1	Fatigue 08/2013
1	Thrombocytopenia (Thrombopenia) 08/2013
1	Disease Progression 04/2013
1	Neoplasms (Cancer) 02/2010
1	Hypoxia (Hypoxemia) 01/2010

Drug/Important Bio-Agent (IBA)

10	pazopanib FDA Link 04/2016 - 01/2010
5	Sunitinib (Sutent)FDA Link 04/2016 - 08/2013
2	Angiogenesis InhibitorsIBA 01/2016 - 06/2011
2	CytokinesIBA 04/2013 - 02/2010
1	Tyrosine Kinase InhibitorsIBA 01/2016
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	AlbuminsIBA 01/2015
1	Alkaline PhosphataseIBA 01/2015
1	Alanine Transaminase (SGPT)IBA 08/2013
1	InterferonsIBA 08/2013
1	Genetic Markers (Genetic Marker)IBA 06/2011
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2010
1	factor AIBA 01/2010
1	Platelet-Derived Growth FactorIBA 01/2010
1	Transcription Factors (Transcription Factor)IBA 01/2010

Therapy/Procedure

1	Aftercare (After-Treatment) 12/2016
1	Therapeutics 04/2016